Table 1.
Anthropometric data at baseline and after rhGH therapy onset
| Chronological age (bone age) | Height (SDS) | Growth velocity (SDS) | DXA (baseline) | DXA2 | DXA3 | DXA4 | ||
|---|---|---|---|---|---|---|---|---|
| Patient 1 | ||||||||
| Baseline | 15.5 (12.0) | 125.5 (−5.9) | — | Weight (kg) | 36.7 | 36.8 | 35.9 | 61.3 |
| 1st year | 16.5 (13.0) | 137.8 (−4.2) | 12.8 (+31.0) | BMI (kg/m2) | 23.3 | 20.75 | 20.91 | 27.1 |
| 2nd year | 17.5 (14.0) | 143.8 (−3.1) | 6.0 (+21.0) | BMD (g/cm2) | 0.6440 | 0.733 | 0.781 | 1,050 |
| 3rd year | 18.5 (14.0) | 146.4 (−2.6) | 2.6 (+14.4) | BMD (Z‐score) | −3.7 | −2.7 | −2.2 | 0.4 |
| 4th year | 19.5 | 148.8 (−2.2) | 2.3 (+12.5) | TBS | 1,270 | 1,280 | 1,400 | N.A. |
| Patient 2 | ||||||||
| Baseline | 8.1 (6.5) | 100.4 (−5.0) | — | Weight (kg) | 17.5 | 18.5 | 20.2 | 50.4 |
| 1st year | 9.0 (7.5) | 114.0 (−3.2) | 14.2 (+11.4) | BMI (kg/m2) | 17.4 | 15.75 | 14.76 | 20.81 |
| 2nd year | 10.0 (9.0) | 125.1 (−2.0) | 11.1 (+5.5) | BMD (g/cm2) | 0.478 | 0.515 | 0.523 | 0.825 |
| 3rd year | 11.1 (10.5) | 133.2 (−1.5) | 8.2 (+1.4) | BMD (Z‐score) | −1.3 | −0.7 | −1.0 | −1.0 |
| 4th year | 12.0 (11.3) | 138.5 (−1.6) | 5.7 (−1.2) | TBS | 1,260 | 1,270 | 1,360 | N.A. |
| 5th year | 13.0 (12.5) | 146.2 (−1.2) | 7.8 (+2.8) | |||||
| 6 year & 6 month | 14.5 (13.5) | 152.9 (−0.7) | 5.0 (+1.2) | |||||
| Patient 3 | ||||||||
| Baseline | 6.0 (3.5) | 84.5 (−6.7) | — | Weight (kg) | 9.8 | 11.5 | 12.7 | 36 |
| 1st year | 7.0 (5.0) | 98.5 (−4.4) | 14.6 (+9.3) | BMI (kg/m2) | 13.7 | 15.77 | 14.76 | 18.90 |
| 2nd year | 8.0 (6.5) | 106.9 (−3.6) | 8.4 (+3.7) | BMD (g/cm2) | 0.397 | 0.446 | 0.470 | 0.678 |
| 3rd year | 9.0 (7.5) | 114.2 (−3.2) | 7.4 (+1.1) | BMD (Z‐score) | −2.2 | −1.4 | −1.0 | −1.1 |
| 4th year | 10.0 (8.8) | 119.3 (−2.9) | 5.4 (+0.5) | TBS | 1,260 | 1,270 | 1,360 | N.A. |
| 5th year | 10.9 (10.0) | 126.4 (−2.5) | 7.1 (+1.3) | |||||
| 6 year & 6 month | 12.3 (11.3) | 137.5 (−1.9) | 7.4 (+0.5) | |||||
SDS, standard deviation score. Bone mineral density (BMD) and trabecular bone structure (TBS) in DXA (dual‐energy absorptiometry analysis) in the three patients before (baseline) and after 6 months (DXA2), 1 year (DXA3), and 6.5 years (DXA4) of rhGH therapy onset (patient 1 received 4.5 years of treatment, and patients 2 and 3 remain on treatment). All of the DXA data refer to lumbar spine (L1–L4) (N.A., not available).